| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Method |
P, F |
| Pretreatment |
EDTA |
| Positive control |
Infected tissue |
| Dilution |
1:10 - 1:30 |
| Isotype |
Ig |
| Localization |
Cell wall |
Rabbit anti-Toxoplasma gondii
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Concentrate |
RUO |
RBK060-05 |
-
|
| Host |
Mouse |
| Clone |
51RAD01 |
| Format |
Concentrate |
| Method |
F, P, WB, IP, IF |
| Pretreatment |
Citrate |
| Positive control |
Testis |
| Dilution |
1:25 - 1:50 |
| Isotype |
Mouse IgG1 |
| Localization |
Nucleus |
RAD51
|
Diagnostic Biosystems |
51RAD01 |
1 ml |
Concentrate |
RUO |
MOB324 |
-
|
| Host |
Mouse |
| Clone |
51RAD01 |
| Format |
Concentrate |
| Method |
F, P, WB, IP, IF |
| Pretreatment |
Citrate |
| Positive control |
Testis |
| Dilution |
1:25 - 1:50 |
| Isotype |
Mouse IgG1 |
| Localization |
Nucleus |
RAD51
|
Diagnostic Biosystems |
51RAD01 |
0.1 ml |
Concentrate |
RUO |
MOB324-01 |
-
|
| Host |
Mouse |
| Clone |
51RAD01 |
| Format |
Concentrate |
| Method |
F, P, WB, IP, IF |
| Pretreatment |
Citrate |
| Positive control |
Testis |
| Dilution |
1:25 - 1:50 |
| Isotype |
Mouse IgG1 |
| Localization |
Nucleus |
RAD51
|
Diagnostic Biosystems |
51RAD01 |
0.5 ml |
Concentrate |
RUO |
MOB324-05 |
-
|
| Host |
Mouse |
| Clone |
66.4.C2 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Normal kidney or renal cell carcinoma. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG2a /κ |
| Immunogen |
Native from human renal cortical tissue homogenate |
| Localization |
Membranous and Cytoplasm |
RCC
|
Zeta Corporation |
66.4.C2 |
1ml |
Concentrate |
CE/IVD |
Z2256ML |
-
|
| Host |
Mouse |
| Clone |
66.4.C2 |
| Format |
Ready-to-use |
| Reactivity |
- |
| Method |
P |
| Positive control |
Normal kidney or renal cell carcinoma. |
| Dilution |
- |
| Isotype |
IgG2a /κ |
| Immunogen |
Native from human renal cortical tissue homogenate |
| Localization |
Membranous and Cytoplasm |
RCC
|
Zeta Corporation |
66.4.C2 |
7 ml |
Ready-to-use |
CE/IVD |
Z2256MP |
-
|
| Host |
Mouse |
| Clone |
66.4.C2 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Normal kidney or renal cell carcinoma. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG2a /κ |
| Immunogen |
Native from human renal cortical tissue homogenate |
| Localization |
Membranous and Cytoplasm |
RCC
|
Zeta Corporation |
66.4.C2 |
0.5 ml |
Concentrate |
CE/IVD |
Z2256MS |
-
|
| Host |
Mouse |
| Clone |
66.4.C2 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Normal kidney or renal cell carcinoma. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG2a /κ |
| Immunogen |
Native from human renal cortical tissue homogenate |
| Localization |
Membranous and Cytoplasm |
RCC
|
Zeta Corporation |
66.4.C2 |
0.1 ml |
Concentrate |
CE/IVD |
Z2256MT |
-
|
| Host |
Mouse |
| Clone |
PN-15 |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Fast Enzyme |
| Positive control |
Normal Kidney, Renal Cell Carcinoma |
| Dilution |
1:100 - 1:200 |
| Localization |
Cytoplasm, Cell Membrane |
Renal Cell Carcinoma, gp200
|
Diagnostic Biosystems |
PN-15 |
1 ml |
Concentrate |
CE/IVD |
MOB465 |
-
|
| Host |
Mouse |
| Clone |
PN-15 |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Fast Enzyme |
| Positive control |
Normal Kidney, Renal Cell Carcinoma |
| Dilution |
1:100 - 1:200 |
| Localization |
Cytoplasm, Cell Membrane |
Renal Cell Carcinoma, gp200
|
Diagnostic Biosystems |
PN-15 |
0.1 ml |
Concentrate |
CE/IVD |
MOB465-01 |
-
|
| Host |
Mouse |
| Clone |
PN-15 |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Fast Enzyme |
| Positive control |
Normal Kidney, Renal Cell Carcinoma |
| Dilution |
1:100 - 1:200 |
| Localization |
Cytoplasm, Cell Membrane |
Renal Cell Carcinoma, gp200
|
Diagnostic Biosystems |
PN-15 |
0.5 ml |
Concentrate |
CE/IVD |
MOB465-05 |
-
|
| Host |
Mouse |
| Clone |
PN-15 |
| Format |
Ready-to-use |
| Method |
F, P |
| Pretreatment |
Fast Enzyme |
| Positive control |
Normal Kidney, Renal Cell Carcinoma |
| Dilution |
- |
| Localization |
Cytoplasm, Cell Membrane |
Renal Cell Carcinoma, gp200
|
Diagnostic Biosystems |
PN-15 |
6 ml |
Ready-to-use |
CE/IVD |
PDM169 |
-
|
| Host |
Mouse |
| Clone |
1F8 (Rb1) |
| Format |
Concentrate |
| Method |
F, P, IP, WB |
| Pretreatment |
EDTA |
| Positive control |
Colon Carcinoma |
| Dilution |
1:25 - 1:75 |
| Isotype |
Mouse IgG1 |
| Localization |
Nucleus |
Retinoblastoma (Rb)
|
Diagnostic Biosystems |
1F8 (Rb1) |
1 ml |
Concentrate |
CE/IVD |
MOB220 |
-
|
| Host |
Mouse |
| Clone |
1F8 (Rb1) |
| Format |
Concentrate |
| Method |
F, P, IP, WB |
| Pretreatment |
EDTA |
| Positive control |
Colon Carcinoma |
| Dilution |
1:25 - 1:75 |
| Isotype |
Mouse IgG1 |
| Localization |
Nucleus |
Retinoblastoma (Rb)
|
Diagnostic Biosystems |
1F8 (Rb1) |
0.1 ml |
Concentrate |
CE/IVD |
MOB220-01 |
-
|
| Host |
Mouse |
| Clone |
1F8 (Rb1) |
| Format |
Concentrate |
| Method |
F, P, IP, WB |
| Pretreatment |
EDTA |
| Positive control |
Colon Carcinoma |
| Dilution |
1:25 - 1:75 |
| Isotype |
Mouse IgG1 |
| Localization |
Nucleus |
Retinoblastoma (Rb)
|
Diagnostic Biosystems |
1F8 (Rb1) |
0.5 ml |
Concentrate |
CE/IVD |
MOB220-05 |
-
|
| Host |
Mouse |
| Clone |
1F8 (Rb1) |
| Format |
Ready-to-use |
| Method |
F, P |
| Pretreatment |
EDTA |
| Positive control |
Colon Carcinoma |
| Dilution |
- |
| Isotype |
Mouse IgG1 |
| Localization |
Nucleus |
Retinoblastoma (Rb)
|
Diagnostic Biosystems |
1F8 (Rb1) |
6 ml |
Ready-to-use |
CE/IVD |
PDM111 |
-
|
| Host |
Mouse |
| Clone |
1F8 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
HIER |
| Positive control |
Colon cancer |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Human Rb1 protein fragment of 283 amino acid residues |
| Localization |
Nucleus |
Retinoblastoma (Rb)
|
Zeta Corporation |
1F8 |
1 ml |
Concentrate |
CE/IVD |
Z2651ML |
-
|
| Host |
Mouse |
| Clone |
1F8 |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
HIER |
| Positive control |
Colon cancer |
| Dilution |
- |
| Isotype |
IgG1 /κ |
| Immunogen |
Human Rb1 protein fragment of 283 amino acid residues |
| Localization |
Nucleus |
Retinoblastoma (Rb)
|
Zeta Corporation |
1F8 |
7 ml |
Ready-to-use |
CE/IVD |
Z2651MP |
-
|
| Host |
Mouse |
| Clone |
1F8 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
HIER |
| Positive control |
Colon cancer |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Human Rb1 protein fragment of 283 amino acid residues |
| Localization |
Nucleus |
Retinoblastoma (Rb)
|
Zeta Corporation |
1F8 |
0.5 ml |
Concentrate |
CE/IVD |
Z2651MS |
-
|
| Host |
Mouse |
| Clone |
1F8 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
HIER |
| Positive control |
Colon cancer |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Human Rb1 protein fragment of 283 amino acid residues |
| Localization |
Nucleus |
Retinoblastoma (Rb)
|
Zeta Corporation |
1F8 |
0.1 ml |
Concentrate |
CE/IVD |
Z2651MT |
-
|
| Host |
Mouse |
| Clone |
6F3.1 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Small intestine (Peyer’s patch), tonsil, thymus |
| Dilution |
1:100 |
| Isotype |
IgG2a Kappa |
| Immunogen |
GST - tagged recombinant protein corresponding to human ROR gamma T |
| Localization |
Nucleus |
ROR gamma T
|
Biocare Medical |
6F3.1 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3208A |
-
|
| Host |
Mouse |
| Clone |
6F3.1 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Small intestine (Peyer’s patch), tonsil, thymus |
| Dilution |
1:100 |
| Isotype |
IgG2a Kappa |
| Immunogen |
GST - tagged recombinant protein corresponding to human ROR gamma T |
| Localization |
Nucleus |
ROR gamma T
|
Biocare Medical |
6F3.1 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3208B |
-
|
| Host |
Mouse |
| Clone |
6F3.1 |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Small intestine (Peyer’s patch), tonsil, thymus |
| Dilution |
- |
| Isotype |
IgG2a Kappa |
| Immunogen |
GST - tagged recombinant protein corresponding to human ROR gamma T |
| Localization |
Nucleus |
ROR gamma T
|
Biocare Medical |
6F3.1 |
6 ml |
Ready-to-use |
CE/IVD |
API3208AA |
-
|
| Host |
Rabbit |
| Clone |
EPMGHR2 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
EDTA |
| Positive control |
Lung carcinoma |
| Dilution |
1:100 |
| Isotype |
IgG |
| Immunogen |
Synthetic peptide within Human ROS1 aa 2050-2150. The exact sequence is proprietary. |
| Localization |
Cytoplasm (diffuse) |
ROS1
|
Biocare Medical |
EPMGHR2 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3240A |
-
|
| Host |
Rabbit |
| Clone |
EPMGHR2 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
EDTA |
| Positive control |
Lung carcinoma |
| Dilution |
1:100 |
| Isotype |
IgG |
| Immunogen |
Synthetic peptide within Human ROS1 aa 2050-2150. The exact sequence is proprietary. |
| Localization |
Cytoplasm (diffuse) |
ROS1
|
Biocare Medical |
EPMGHR2 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3240B |
-
|
| Host |
Rabbit |
| Clone |
EPMGHR2 |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
EDTA |
| Positive control |
Lung carcinoma |
| Dilution |
- |
| Isotype |
IgG |
| Immunogen |
Synthetic peptide within Human ROS1 aa 2050-2150. The exact sequence is proprietary. |
| Localization |
Cytoplasm (diffuse) |
ROS1
|
Biocare Medical |
EPMGHR2 |
7 ml |
Ready-to-use |
CE/IVD |
ALI3240G7 |
-
|
| Host |
Rabbit |
| Clone |
EPMGHR2 |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
EDTA |
| Positive control |
Lung carcinoma |
| Dilution |
- |
| Isotype |
IgG |
| Immunogen |
Synthetic peptide within Human ROS1 aa 2050-2150. The exact sequence is proprietary. |
| Localization |
Cytoplasm (diffuse) |
ROS1
|
Biocare Medical |
EPMGHR2 |
6 ml |
Ready-to-use |
CE/IVD |
API3240AA |
-
|
| Host |
Rabbit |
| Clone |
EPMGHR2 |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
EDTA |
| Positive control |
Lung carcinoma |
| Dilution |
- |
| Isotype |
IgG |
| Immunogen |
Synthetic peptide within Human ROS1 aa 2050-2150. The exact sequence is proprietary. |
| Localization |
Cytoplasm (diffuse) |
ROS1
|
Diagnostic Biosystems |
EPMGHR2 |
6 ml |
Ready-to-use |
CE/IVD |
RMPD108 |
-
|
| Host |
Rabbit |
| Clone |
ZR400 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
HIER or PIER |
| Positive control |
Human brain, lung adenocarcinoma, or primary glioblastoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Recombinant fragment corresponding to the cytoplasmic domain of human ROS1 protein |
| Localization |
cell surface |
ROS1
|
Zeta Corporation |
ZR400 |
1 ml |
Concentrate |
RUO |
Z2756RL-R |
-
|
| Host |
Rabbit |
| Clone |
ZR400 |
| Format |
reasy-to-use |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
HIER or PIER |
| Positive control |
Human brain, lung adenocarcinoma, or primary glioblastoma |
| Dilution |
--- |
| Isotype |
IgG |
| Immunogen |
Recombinant fragment corresponding to the cytoplasmic domain of human ROS1 protein |
| Localization |
cell surface |
ROS1
|
Zeta Corporation |
ZR400 |
7 ml |
reasy-to-use |
RUO |
Z2756RP-R |
-
|
| Host |
Rabbit |
| Clone |
ZR400 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
HIER or PIER |
| Positive control |
Human brain, lung adenocarcinoma, or primary glioblastoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Recombinant fragment corresponding to the cytoplasmic domain of human ROS1 protein |
| Localization |
cell surface |
ROS1
|
Zeta Corporation |
ZR400 |
0.5 ml |
Concentrate |
RUO |
Z2756RS-R |
-
|
| Host |
Rabbit |
| Clone |
ZR400 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
HIER or PIER |
| Positive control |
Human brain, lung adenocarcinoma, or primary glioblastoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Recombinant fragment corresponding to the cytoplasmic domain of human ROS1 protein |
| Localization |
cell surface |
ROS1
|
Zeta Corporation |
ZR400 |
0.1 ml |
Concentrate |
RUO |
Z2756RT-R |
-
|
| Host |
Mouse |
| Clone |
9H8 |
| Format |
Concentrate |
| Method |
F, P, IP, IF, WB |
| Pretreatment |
Citrate |
| Positive control |
Tonsil |
| Dilution |
1:50 - 1:100 |
| Isotype |
Mouse IgG1 |
| Localization |
Nucleus |
RPA (p34) (Replication Protein A)
|
Diagnostic Biosystems |
9H8 |
1 ml |
Concentrate |
CE/IVD |
MOB329 |
-
|
| Host |
Mouse |
| Clone |
9H8 |
| Format |
Concentrate |
| Method |
F, P, IP, IF, WB |
| Pretreatment |
Citrate |
| Positive control |
Tonsil |
| Dilution |
1:50 - 1:100 |
| Isotype |
Mouse IgG1 |
| Localization |
Nucleus |
RPA (p34) (Replication Protein A)
|
Diagnostic Biosystems |
9H8 |
0.1 ml |
Concentrate |
CE/IVD |
MOB329-01 |
-
|
| Host |
Mouse |
| Clone |
9H8 |
| Format |
Concentrate |
| Method |
F, P, IP, IF, WB |
| Pretreatment |
Citrate |
| Positive control |
Tonsil |
| Dilution |
1:50 - 1:100 |
| Isotype |
Mouse IgG1 |
| Localization |
Nucleus |
RPA (p34) (Replication Protein A)
|
Diagnostic Biosystems |
9H8 |
0.5 ml |
Concentrate |
CE/IVD |
MOB329-05 |
-
|
| Host |
Mouse |
| Clone |
4C4.9 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Melanoma. |
| Dilution |
1:150 - 1:300 |
| Isotype |
IgG2a /κ |
| Immunogen |
Purified bovine brain S100 p |
| Localization |
Cytoplasm and Nucleus |
S-100
|
Zeta Corporation |
4C4.9 |
1ml |
Concentrate |
CE/IVD |
Z2055ML |
-
|
| Host |
Mouse |
| Clone |
4C4.9 |
| Format |
Ready-to-use |
| Reactivity |
- |
| Method |
P |
| Positive control |
Melanoma. |
| Dilution |
- |
| Isotype |
IgG2a /κ |
| Immunogen |
Purified bovine brain S100 p |
| Localization |
Cytoplasm and Nucleus |
S-100
|
Zeta Corporation |
4C4.9 |
7 ml |
Ready-to-use |
CE/IVD |
Z2055MP |
-
|
| Host |
Mouse |
| Clone |
4C4.9 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Melanoma. |
| Dilution |
1:150 - 1:300 |
| Isotype |
IgG2a /κ |
| Immunogen |
Purified bovine brain S100 p |
| Localization |
Cytoplasm and Nucleus |
S-100
|
Zeta Corporation |
4C4.9 |
0.5 ml |
Concentrate |
CE/IVD |
Z2055MS |
-
|
| Host |
Mouse |
| Clone |
4C4.9 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Melanoma. |
| Dilution |
1:150 - 1:300 |
| Isotype |
IgG2a /κ |
| Immunogen |
Purified bovine brain S100 p |
| Localization |
Cytoplasm and Nucleus |
S-100
|
Zeta Corporation |
4C4.9 |
0.1 ml |
Concentrate |
CE/IVD |
Z2055MT |
-
|
| Host |
Rabbit |
| Clone |
SP50 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Breast Carcinoma |
| Dilution |
1:100 |
| Isotype |
Rabbit IgG |
| Immunogen |
Synthetic peptide derived from the region of human S6 ribosomal that contains phosphorylated serines 235 and 236 |
| Localization |
Cytoplasm |
S6 Ribosomal (phospho S235/236)
|
Zytomed Systems GmbH |
SP50 |
1 ml |
Concentrate |
RUO |
519-3504 |
-
|
| Host |
Mouse |
| Clone |
SH-B1 |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Trypsin or Fast Enzyme |
| Positive control |
Melanoma |
| Dilution |
1:50 - 1:100 |
| Isotype |
Mouse IgG1 |
| Localization |
Cytoplasm |
S100
|
Diagnostic Biosystems |
SH-B1 |
1 ml |
Concentrate |
CE/IVD |
MOB111 |
-
|
| Host |
Mouse |
| Clone |
SH-B1 |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Trypsin or Fast Enzyme |
| Positive control |
Melanoma |
| Dilution |
1:50 - 1:100 |
| Isotype |
Mouse IgG1 |
| Localization |
Cytoplasm |
S100
|
Diagnostic Biosystems |
SH-B1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB111-01 |
-
|
| Host |
Mouse |
| Clone |
SH-B1 |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Trypsin or Fast Enzyme |
| Positive control |
Melanoma |
| Dilution |
1:50 - 1:100 |
| Isotype |
Mouse IgG1 |
| Localization |
Cytoplasm |
S100
|
Diagnostic Biosystems |
SH-B1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB111-05 |
-
|
| Host |
Mouse |
| Clone |
4C4.9 |
| Format |
Concentrate |
| Method |
F, P |
| Positive control |
Melanoma |
| Dilution |
1:50 - 1:100 |
| Isotype |
Mouse |
| Localization |
Cytoplasm |
S100
|
Diagnostic Biosystems |
4C4.9 |
1 ml |
Concentrate |
CE/IVD |
MOB377 |
-
|
| Host |
Mouse |
| Clone |
4C4.9 |
| Format |
Concentrate |
| Method |
F, P |
| Positive control |
Melanoma |
| Dilution |
1:50 - 1:100 |
| Isotype |
Mouse |
| Localization |
Cytoplasm |
S100
|
Diagnostic Biosystems |
4C4.9 |
0.1 ml |
Concentrate |
CE/IVD |
MOB377-01 |
-
|
| Host |
Mouse |
| Clone |
4C4.9 |
| Format |
Concentrate |
| Method |
F, P |
| Positive control |
Melanoma |
| Dilution |
1:50 - 1:100 |
| Isotype |
Mouse |
| Localization |
Cytoplasm |
S100
|
Diagnostic Biosystems |
4C4.9 |
0.5 ml |
Concentrate |
CE/IVD |
MOB377-05 |
-
|
| Host |
Mouse |
| Clone |
SH-B1 |
| Format |
Ready-to-use |
| Method |
F, P |
| Pretreatment |
Trypsin or Fast Enzyme |
| Positive control |
Melanoma |
| Dilution |
- |
| Isotype |
Mouse IgG1 |
| Localization |
Cytoplasm |
S100
|
Diagnostic Biosystems |
SH-B1 |
6 ml |
Ready-to-use |
CE/IVD |
PDM088 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Ready-to-use |
| Method |
F, P |
| Pretreatment |
Trypsin or Pepsin (optional) |
| Positive control |
Melanoma |
| Dilution |
- |
| Isotype |
Rabbit IgG |
| Localization |
Cytoplasm |
S100
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR008 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Trypsin or Pepsin (optional) |
| Positive control |
Melanoma |
| Dilution |
1:50 - 1:200 |
| Isotype |
Rabbit IgG |
| Localization |
Cytoplasm |
S100
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP035 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Trypsin or Pepsin (optional) |
| Positive control |
Melanoma |
| Dilution |
1:50 - 1:200 |
| Isotype |
Rabbit IgG |
| Localization |
Cytoplasm |
S100
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP035-01 |
-
|